The Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Attending this year’s conference are some of our team members below who will be available for meetings on site.
Get in touch now to speak to one of our team on or off site about Diaceutics solutions which could work for your company’s targeted therapy launch.
Background The standard of care for AML patients (pts) has not changed in 40 yrs. Molecular biomarkers FLT3 and IDH1/2 are being tested for prognosis and risk stratification and recent trial results show these will be effective for targeted therapies. We analyzed real world data from a leading clinical lab (BioReference Laboratories Inc) to evaluate the frequency of pts eligible for FLT3 and IDH therapies.